Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for International Stem Cell Corp. (ISCO : OTC)

• Company Description    International Stem Cell Corporation is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO's objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be differentiated into the specific cell types required for transplant. It has developed manufacturing protocols to produce the cells minimizing contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields. Number of Employees: 29

• Price / Volume Information    Yesterday's Closing Price: $0.50 Daily Weekly Monthly 20 Day Moving Average: 2,196 shares Shares Outstanding: 8.00 (millions) Market Capitalization: $4.00 (millions) Beta: 0.80 52 Week High: $0.80 52 Week Low: $0.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.36% 23.03% 12 Week 13.64% 27.71% Year To Date 5.71% 29.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5950 PRIESTLY DRIVE - CARLSBAD,CA 92008 USA ph: 760-940-6383 fax: 760-476-0600 ir@intlstemcell.com http://www.internationalstemcell.com

• General Corporate Information    Officers Andrey Semechkin - Chief Executive Officer and Co-Chairman Donald A. Wright - Co-Chairman Sophia Garnette - Vice President Legal Affairs and Operations Russell Kern - Executive Vice President and Chief Scientific Offi Paul V. Maier - Director Peer Information International Stem Cell Corp. (CORR.) International Stem Cell Corp. (RSPI) International Stem Cell Corp. (CGXP) International Stem Cell Corp. (BGEN) International Stem Cell Corp. (GTBP) International Stem Cell Corp. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 460378201 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/12/22 Share - Related Items Shares Outstanding: 8.00 Most Recent Split Date: 7.00 (0.01:1) Beta: 0.80 Market Capitalization: $4.00 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 0.53 EPS Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: 100.00% Sales Growth vs. Year Ago Period: 21.83% vs. Previous Quarter: 9.60% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -18.48 12/31/21 - -29.01 09/30/21 - -35.33 Current Ratio 03/31/22 - 0.62 12/31/21 - 0.54 09/30/21 - 0.57 Quick Ratio 03/31/22 - 0.34 12/31/21 - 0.27 09/30/21 - 0.31 Operating Margin 03/31/22 - -12.87 12/31/21 - -21.74 09/30/21 - -28.34 Net Margin 03/31/22 - -4.10 12/31/21 - -12.53 09/30/21 - -18.64 Pre-Tax Margin 03/31/22 - -4.10 12/31/21 - -12.53 09/30/21 - -18.64 Book Value 03/31/22 - -0.56 12/31/21 - -0.57 09/30/21 - -0.54 Inventory Turnover 03/31/22 - 2.58 12/31/21 - 2.64 09/30/21 - 2.72 Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©